克里斯汀满天星三部曲,轻快的嘴唇完整版,中文字Dl幕岳和女胥电影

HIV抑制劑GS-6207

NMR下載 COA and HPLC MSDS下載
names：
Lenacapavir
CAS號：
2189684-44-2
MDL Number： No data available
MF(分子式)： C39H32ClF10N7O5S2 MW(分子量)： 968.28
EINECS:No data available Reaxys Number:No data available
Pubchem ID:133082658 Brand:BIOFOUNT

HIV 抑制劑GS-6207(2189684-44-2,Lenacapavir,GS-6207)是一種 HIV-1 衣殼抑制劑。在 MT-4 細胞中，Lenacapavir 具有抗 HIV 活性，EC₅₀ 為 100 pM，在外周血單個核細胞中，對 23 種來自不同亞型的 HIV-1 臨床分離株的平均 EC₅₀ 為 50 pM (20-160 pM)。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	庫存描述	數量	總計 (￥)
YZM000675-10mg	10mg	>97%	￥ 2230.00	￥ 2230.00	1-3天	- +	￥ 0.00
YZM000675-5mg	5mg	>97%	￥ 1420.00	￥ 1420.00	1-3天	- +	￥ 0.00
YZM000675-1mg	1mg	>97%	￥ 500.00	￥ 500.00	1-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	HIV-1衣殼抑制劑GS-6207(2189684-44-2);GS-6207;
英文別名	GS-6207(2189684-44-2);GS-CA1;Lenacapavir;
CAS號	2189684-44-2
Inchi	InChI = 1S / C39H32ClF10N7O5S2 / c1-36（2,63（3,59）60）10-9-21-5-6-22（23-7-8-26（40）30-32（23）57（ 17-37（43,44）45）54-35（30）55-64（4,61）62）31（51-21）27（13-18-11-19（41）14-20（42） 12-18）52-28（58）16-56-34-29（33（53-56）39（48,49）50）24-15-25（24）38（34,46）47 / h5- 8,11-12,14,24-25,27H，13,15-17H2,1-4H3，（H，52,58）（H，54,55）/ t24-，25 +，27- / m0 / s1
InchiKey	BRYXUCLEHAUSDY-WEWMWRJBSA-N
分子式 Formula	C39H32ClF10N7O5S2
分子量 Molecular Weight	968.28
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions	-20°C

HIV抑制劑GS-6207(2189684-44-2,Lenacapavir,GS-6207)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:GS-6207試劑,GS-6207雜質,GS-6207中間體,GS-6207密度,GS-6207溶解度,GS-6207旋光度,GS-6207閃點,GS-6207熔點,GS-6207結構式,GS-6207購買,

產品說明	HIV-1衣殼抑制劑GS-6207(2189684-44-2,Lenacapavir,GS-6207)是一種有效的HIV-1衣殼的抑制劑
Introduction	HIV-1衣殼抑制劑GS-6207(2189684-44-2,Lenacapavir,GS-6207)is aHIV capsidinhibitor. GS207 shows antiIV activity with anEC50of 100 pM in MT cells.
Application1	GS207 displays a meanEC50of 50 pM (2060 pM) against 23 HIV clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).
Application2
Application3

HIV-1衣殼抑制劑GS-6207(2189684-44-2,Lenacapavir,GS-6207)藥理學：

Lenacapavir (GS-6207) 是一種 HIV-1 衣殼抑制劑。在 MT-4 細胞中，Lenacapavir 具有抗 HIV 活性，EC₅₀ 為 100 pM，在外周血單個核細胞中，對 23 種來自不同亞型的 HIV-1 臨床分離株的平均 EC₅₀ 為 50 pM (20-160 pM)。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV Phase 2 Recruiting 2020-08-27

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Re

Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in HIV-1 Infected Adults Phase 1 Completed 2020-07-08

Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227.

John O Link, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Jul 1.

HIV-1衣殼抑制劑GS-6207(2189684-44-2,Lenacapavir,GS-6207)參考文獻：

1、Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE) Brief

Summary: The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with HIV (PLWH).

2、Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

Brief Summary: The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR).

3、Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in HIV-1 Infected Adults

Brief Summary: This study has 2 parts: Part A (Cohorts 1-5) and Part B (Cohorts 6-8). The primary objectives of this study are: Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207) compared to placebo in HIV-1 infected adults who are antiretroviral treatment naive or are experienced but capsid inhibitor (CAI) naive. Part B: To evaluate the short-term antiviral activity of tenofovir alafenamide (TAF) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day 10 in HIV-1 infected adult subjects who are antiretroviral treatment naïve or are experienced but without resistance to TAF.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開